Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA. "We are pleased to share presentations on selinexor at this year's annual meeting," said Reshma Rangwala , MD, PhD, Chief Medical Officer and Head of Research at Karyopharm. "The data being presented demonstrate our commitment, as well as that of our partners to our ongoing work in multiple myeloma and myelofibrosis." Details for the ASH 2024 selected Karyopharm abstracts are as follows: Abstract Title Presentation Type Abstract # Session Date/Time Multiple Myeloma Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Poster Saturday, December 7, 2024 5:30pm - 7:30pm PST/ 8:30pm - 10:30pm EST Myelofibrosis Selinexor Depletes Ruxolitinib
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Robert W. Baird from $75.00 to $54.00. They now have an "outperform" rating on the stock.MarketBeat
- Karyopharm Announces 1-for-15 Reverse Stock Split [Yahoo! Finance]Yahoo! Finance
- Karyopharm Announces 1-for-15 Reverse Stock SplitPR Newswire
KPTI
Earnings
- 2/19/25 - Beat
KPTI
Sec Filings
- 3/6/25 - Form 4
- 3/6/25 - Form 4
- 3/6/25 - Form 4
- KPTI's page on the SEC website